p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes

被引：25

作者：

Frisan, Emilie ^{[1
,2
,3
,5
]}

Pawlikowska, Patrycja ^{[1
,2
,3
]}

Pierre-Eugene, Cecile ^{[1
,2
,3
,4
]}

Viallon, Vivian ^{[5
,6
]}

Gibault, Laure ^{[5
,7
]}

Park, Sophie ^{[1
,2
,3
,5
,8
]}

Mayeux, Patrick ^{[1
,2
,3
]}

Dreyfus, Francois ^{[1
,2
,3
,5
,8
]}

Porteu, Francoise ^{[1
,2
,3
]}

Fontenay, Michaela ^{[1
,2
,3
,5
]}

机构：

[1] Inst Cochin, Dept Immunol Hematol, Paris, France

[2] INSERM, U1016, F-75654 Paris 13, France

[3] CNRS, UMR 8104, F-75700 Paris, France

[4] Hop Broca Cochin Hotel Dieu, Assistance Publ Hop Paris, Serv Hematol Biol, Paris, France

[5] Univ Paris 05, Fac Med, Paris, France

[6] Hop Cochin, Assistance Publ Hop Paris, Dept Epidemiol & Biostat, F-75679 Paris 14, France

[7] Hop Cochin, Assistance Publ Hop Paris, Serv Anatomopathol, F-75679 Paris 14, France

[8] Hop Cochin, Assistance Publ Hop Paris, Serv Med Interne, Unite Fonct Hematol, F-75679 Paris 14, France

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷 / 11期

关键词：

myelodysplastic syndromes; red cells; MAPkinase; erythropoiesis-stimulating agents; PHOSPHOINOSITIDE; 3-KINASE/AKT; PLUS ERYTHROPOIETIN; G-CSF; ANEMIA; PHOSPHORYLATION; DIFFERENTIATION; ACTIVATION; SURVIVAL; LEUKEMIA; PROPOSAL;

D O I：

10.3324/haematol.2010.024349

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Serum erythropoietin level less than 100U/L and a transfusion requirement of less than 2 units per month are the best predictive factors for response to treatment by erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes. To investigate the factors influencing the response to erythropoiesis-stimulating agents, we enrolled 127 low/int-1 myelodysplastic syndrome patients at diagnosis in a biological study of erythropoiesis. The 54 non-responders had a significantly lower number of burst-forming unit-erythroid and colony-forming unit-erythroid than responders. Erythropoietin-dependent proliferation and survival, and phospho (p)-ERK1/2 expression in steady state and after erythropoietin stimulation were defective in cultured erythroblasts. By flow cytometry, p-ERK1/2 was significantly lower in bone marrow CD45(-)/CD71(+)/GPA(-) cells from non-responders compared to responders or controls. Receiver Operator Characteristic curve analysis showed that this flow cytometry test was a sensitive biomarker for predicting the response to erythropoiesis-stimulating agents.

引用

页码：1964 / 1968

页数：5

共 22 条

[1]

Bardet V, 2006, HAEMATOLOGICA, V91, P757

[2] Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes:: a randomized, controlled trial [J].

Casadevall, N ;

Durieux, P ;

Dubois, S ;

Hemery, F ;

Lepage, E ;

Quarré, MC ;

Damaj, G ;

Giraudier, S ;

Guerci, A ;

Laurent, G ;

Dombret, H ;

Chomienne, C ;

Ribrag, V ;

Stamatoullas, A ;

Marie, JP ;

Vekhoff, A ;

Maloisel, F ;

Navarro, R ;

Dreyfus, F ;

Fenaux, P .

BLOOD, 2004, 104 (02) :321-327

[3] Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia [J].

Cheson, Bruce D. ;

Greenberg, Peter L. ;

Bennett, John M. ;

Lowenberg, Bob ;

Wijermans, Pierre W. ;

Nimer, Stephen D. ;

Pinto, Antonio ;

Beran, Miloslav ;

de Witte, Theo M. ;

Stone, Richard M. ;

Mittelman, Moshe ;

Sanz, Guillermo F. ;

Gore, Steven D. ;

Schiffer, Charles A. ;

Kantarjian, Hagop .

BLOOD, 2006, 108 (02) :419-425

[4] In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis [J].

Claessens, YE ;

Bouscary, D ;

Dupont, JM ;

Picard, F ;

Melle, J ;

Gisselbrecht, S ;

Lacombe, C ;

Dreyfus, F ;

Mayeux, P ;

Fontenay-Roupie, M .

BLOOD, 2002, 99 (05) :1594-1601

[5] The MEK-1/ERKs signalling pathway is differentially involved in the self-renewal of early and late avian erythroid progenitor cells [J].

Dazy, S ;

Damiola, F ;

Parisey, N ;

Beug, H ;

Gandrillon, O .

ONCOGENE, 2003, 22 (58) :9205-9216

[6] ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia [J].

Gregorj, Chiara ;

Ricciardi, Maria R. ;

Petrucci, Maria T. ;

Scerpa, Maria C. ;

De Cave, Fabiana ;

Fazi, Paola ;

Vignetti, Marco ;

Vitale, Antonella ;

Mancini, Marco ;

Cimino, Giuseppe ;

Palmieri, Salvatore ;

Di Raimondo, Francesco ;

Specchia, Giorgina ;

Fabbiano, Francesco ;

Cantore, Nicola ;

Mosna, Federico ;

Camera, Andrea ;

Luppi, Mario ;

Annino, Luciana ;

Miraglia, Eustachio ;

Fioritoni, Giuseppe ;

Ronco, Francesca ;

Meloni, Giovanna ;

Mandelli, Franco ;

Andreeff, Michael ;

Milella, Michele ;

Foa, Robin ;

Tafuri, Agostino .

BLOOD, 2007, 109 (12) :5473-5476

[7] A METHOD OF COMPARING THE AREAS UNDER RECEIVER OPERATING CHARACTERISTIC CURVES DERIVED FROM THE SAME CASES [J].

HANLEY, JA ;

MCNEIL, BJ .

RADIOLOGY, 1983, 148 (03) :839-843

[8] Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin:: Results from a randomized phase II study and long-term follow-up of 71 patients [J].

Hellström-Lindberg, E ;

Ahlgren, T ;

Beguin, Y ;

Carlsson, M ;

Carneskog, J ;

Dahl, IM ;

Dybedal, I ;

Grimfors, G ;

Kanter-Lewensohn, L ;

Linder, O ;

Luthman, M ;

Löfvenberg, E ;

Nilsson-Ehle, H ;

Samuelsson, J ;

Tangen, JM ;

Winqvist, I ;

Öberg, G ;

Österborg, A ;

Öst, Å .

BLOOD, 1998, 92 (01) :68-75

[9] A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor:: significant effects on quality of life [J].

Hellström-Lindberg, E ;

Gulbrandsen, N ;

Lindberg, G ;

Ahlgren, T ;

Dahl, IMS ;

Dybedal, I ;

Grimfors, G ;

Hesse-Sundin, E ;

Hjorth, M ;

Kanter-Lewensohn, L ;

Linder, O ;

Luthman, M ;

Löfvenberg, E ;

Öberg, G ;

Porwit-MacDonald, A ;

Rådlund, A ;

Samuelsson, J ;

Tangen, JM ;

Winquist, I ;

Wisloff, F .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (06) :1037-1046

[10] Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model [J].

HellstromLindberg, E ;

Negrin, R ;

Stein, R ;

Krantz, S ;

Lindberg, G ;

Vardiman, J ;

Ost, A ;

Greenberg, P .

BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (02) :344-351

← 1 2 3 →